Listen
In this episode, host Alyssa Watson, DVM, talks with Diane Delmain, DVM, DABVP, about her recent Clinician’s Brief article, “Remdesivir & GS-441524 for Treatment of FIP.” Dr. Delmain discusses the relationship between the two drugs, the hurdles veterinarians face in prescribing them, and the FDA’s stance on compounded GS-441524. She also covers the limitations of retrospective data and the risks associated with unregulated products. Plus, Dr. Delmain shares advice for monitoring for adverse effects and long-term care for cats recovering from FIP.
Watch
Key Takeaways
Remdesivir and GS-441524 have transformed FIP treatment, though veterinarians still face challenges in prescribing them.
The FDA permits GS-441524 compounding for FIP treatment when prescribed by a veterinarian for a specific feline patient.
Unregulated products carry risks due to a lack of quality control, and retrospective data from such cases have significant limitations.
Diagnosing FIP requires a comprehensive approach, and initiating treatment early is essential for affected cats.
Various treatment protocols exist for managing FIP, and these protocols may evolve as clinicians gain access to these medications.
Resources:
Contact:
Where To Find Us:
Website: CliniciansBrief.com/Podcasts
YouTube: Youtube.com/@clinicians_brief
Facebook: Facebook.com/CliniciansBrief
LinkedIn: LinkedIn.com/showcase/CliniciansBrief/
Instagram: @Clinicians.Brief
The Team:
Alyssa Watson, DVM - Host
Alexis Ussery - Producer & Multimedia Specialist